Participated · Series A · Apr 2026

Coultreon Biopharma focuses on developing therapies that target clinically validated pathways in immunology and metabolic diseases, leveraging expertise in disease biology, drug discovery and translational science. Its pipeline centers on selectively modulating salt-inducible kinase (SIK) biology to address key inflammatory pathways. The company's lead program, COL-5671 (formerly O3R-5671), is a highly selective, oral once-daily SIK3 inhibitor currently in Phase 1 clinical studies. Coultreon intends to use the $125M Series A proceeds to support further clinical development of COL-5671. The company is led by CEO Pierre Raboisson and is based in Leuven, Belgium. No revenue, user, founding year or prior-round financial metrics were reported in the article.

Participated · Series A · Feb 2026

Third Arc Bio, launched in 2022, focuses on creating multispecific antibodies that form immune synapses to either activate or inhibit T cells with high precision. Its lead program, ARC101, is a bispecific T-cell engager targeting CLDN6 and is currently in Phase 1 dose-escalation studies for patients with advanced solid tumors. The company’s solid-tumor ARCStim platform and immunology-focused ARCTag (Tethered Agonist) platform underpin a broader pipeline aimed at both cancer and immune-mediated disorders. By localizing immune modulation to sites of disease, Third Arc seeks to improve both efficacy and safety over conventional systemic therapies. The management team includes executives with prior drug-development track records, and a16z General Partner Jorge Conde recently joined the board. Financially, Third Arc Bio has secured at least $217 million in Series A funding (an initial $165 million plus a $52 million extension) in addition to earlier seed capital. Proceeds are earmarked to accelerate its immunology portfolio and advance additional oncology programs into the clinic.

Participated · Equity · Dec 2025

Founded in May 2023 by Nicolas Navarro, APS (Agnostic Production Systems) is building APS CONTROL®, an ecosystem of plug-and-play industrial modules that automatically orchestrate people, machines and existing software within production sites. The product is anchored in the patented Connect and Produce® technology and is designed to be faster, cheaper and lower-risk than traditional manufacturing execution system integrations. Targeting the 26,600 French SMEs and ETIs that have largely been left out of Industry 4.0, APS aims to accelerate the shift toward more agile, sustainable and resilient factories. The company collaborates with the CEA and the CERIS research center (IMT Mines Alès) and plans to launch APS CONTROL® commercially in summer 2026. APS already employs more than 20 people and continues to recruit. Prior to the current equity raise, it secured support from Bpifrance and CRÉALIA Occitanie and non-dilutive bank financing from Banque Populaire du Sud, Caisse d’Épargne Languedoc-Roussillon and the Banque de l’innovation du Crédit Agricole du Languedoc.

Participated · Series C · Feb 2024

Frontier Medicines is a clinical-stage precision medicine company that leverages its proprietary Frontier Platform, a chemoproteomics-powered drug discovery engine using covalent chemistry and machine learning, to unlock hard-to-treat disease-causing proteins. The company is advancing a diversified pipeline of wholly-owned precision medicines focused on oncology and high-value immunology targets. Its lead candidate, FMC-376, is a dual ON+OFF KRASG12C inhibitor currently in the Phase 1/2 PROSPER trial (NCT06244771) and is designed to overcome resistance seen with single-acting KRASG12C inhibitors. Frontier has stated a goal of filing one IND per year as it progresses its programs. The company recently raised additional capital to support development of FMC-376 and to accelerate other preclinical and pipeline programs. Headquarters are listed as Boston and South San Francisco, California. Frontier Medicines is a clinical-stage precision medicine company based in Boston and San Francisco focused on therapies for genetically-defined patient populations in oncology and immunology. Its core product is the Frontier™ Platform, a chemoproteomics-empowered drug discovery engine that leverages covalent chemistry and machine learning to target hard-to-treat disease-causing proteins. The company is advancing a diversified pipeline of wholly-owned precision medicines, with lead candidate FMC-376, a dual inhibitor of on- and off-state KRASG12C. Frontier intends to use the new capital to advance multiple programs, including FMC-376, into clinical studies. The firm is led by CEO Chris Varma and emphasizes transforming treatment for genetically-defined patients. No revenue or user metrics were disclosed in the article. Frontier Medicines deploys integrated technologies in chemoproteomics, covalent drug discovery, and machine learning to generate medicines against proteins previously considered undruggable. The company is advancing a wholly-owned precision oncology pipeline, with a lead program that uniquely targets both the activated and inactive forms of KRASG12C. Frontier intends to use its platform to expand pipeline opportunities across therapeutic areas by leveraging identified protein hotspots. Proceeds from the recent financing are designated to advance research and development of its pipeline and to accelerate foundational technologies across chemoproteomics, covalent discovery, and machine learning. The company also announced a distinguished Scientific Advisory Board to support its programs and highlighted a substantial protein degradation partnership with AbbVie announced late last year. Frontier is expanding operations with a new Boston facility integrated with its South San Francisco headquarters to support bi-coastal growth and R&D capabilities. Frontier Medicines is a pre-clinical stage biopharmaceutical company developing medicines to redefine the course of debilitating diseases, starting with cancer. The company uses a proprietary chemoproteomics platform to chemically interrogate proteins in living systems and identify new binding pockets accessible to small-molecule drug discovery. Its platform also integrates advanced computational approaches and machine learning to accelerate drug discovery. Frontier intends to advance multiple therapeutic programs leveraging this platform. The company closed a $67M Series A to fund research and development, talent acquisition, and advancement of its platform and programs. Co-founders include Chris Varma (CEO), Roberto Zoncu, Ph.D., and Daniel K. Nomura, Ph.D.